Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2024-01-30 00:00:00 ET · period of report 2024-01-30 · accession 0001209191-24-002458 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-30 | 2024-01-30 | VKTX | Lian Brian | Pres, CEO, Dir | M - OptEx | $1.23 | +35.0K | 2.30M | +2% | +$43.0K |
| D | 2024-01-30 | 2024-01-30 | VKTX | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $23.95 | -35.0K | 2.26M | -2% | -$838.2K |
| D | 2024-01-30 | 2024-01-30 | VKTX | Lian Brian | Pres, CEO, Dir | M - OptEx | $0.00 | -35.0K | 99.1K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2024-01-30 | M | A | 35,000 | $1.23 | 2,299,882 | D | — | — | |
| 2 | Common | Common Stock, par value $0.00001 per share | 2024-01-30 | S | D | 35,000 | $23.95 | 2,264,882 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-01-30 | M | D | 35,000 | $0.00 | 99,148 | D | $1.23 · 2018-01-05 to 2027-01-05 | 35,000 Common Stock | (F2) 25% of the shares subject to the option vested on each one year anniversary of the grant date. |